A total of 4377 publications were identified. Of these, 64 met inclusion eligibility criteria: 34 described pharmacokinetic drug interactions and 30 described adverse events ascribed to a drug interaction. Clinically significant pharmacokinetic interactions between aprepitant/fosaprepitant and bosutinib PO, cabazitaxel IV, cyclophosphamide IV, dexamethasone PO, methylprednisolone IV, midazolam PO/IV, oxycodone PO and tolbutamide PO were identified, as were adverse events resulting from an interaction between aprepitant/fosaprepitant and alcohol, anthracyclines, ifosfamide, oxycodone, quetiapine, selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors and warfarin.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Aprepitant and fosaprepitant are moderate and weak CYP3A4 inhibitors, respectively. Aprepitant is also a weak CYP2C9
inducer.
• There are no systematic literature reviews describing interactions between aprepitant or fosaprepitant and other drugs.
WHAT THIS STUDY ADDS
• Using the FDA's definition, reports of clinically significant pharmacokinetic interactions between aprepitant and bosutinib, cabazitaxel, cyclophosphamide, dexamethasone, methylprednisolone, midazolam, oxycodone and tolbutamide were identified.
• Concurrent administration of aprepitant and the following drugs may lead to adverse events: alcohol (impaired cognition), ifosfamide (neurotoxicity), oxycodone (decreased respiratory rate, increased feeling of a 'high'), quetiapine (somnolence), SSRI/SNRIs (vomiting) and warfarin (INR changes). Administration of fosaprepitant and anthracyclines via the same peripheral vein may cause a local reaction at the infusion site.
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Introduction
A neurokinin-1 antagonist such as oral (PO) aprepitant or its intravenous (IV) prodrug, fosaprepitant, together with a 5-HT 3 antagonist and dexamethasone, are strongly recommended for prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in both adult and paediatric cancer patients receiving highly emetogenic chemotherapy [4] [5] [6] [7] . However, aprepitant and fosaprepitant are moderate [8, 9] and weak inhibitors of CYP3A4 [10, 11] , respectively, and there is uncertainty regarding the clinical significance of potential interactions with CYP3A4 substrates. A moderate CYP3A4 inhibitor may increase the area under the concentration vs. time curve (AUC) of a victim drug by twoto up to five-fold and a weak CYP3A4 inhibitor may increase AUC of a victim drug by 1.25-up to two-fold [12] . CYP3A4
inhibitors may also reduce the conversion of a prodrug to its active form [13] . Aprepitant or fosaprepitant may therefore influence the toxicity and the efficacy of concomitantly administered drugs. Recommendations for CINV prevention in children with cancer caution against the use of aprepitant with antineoplastic agents which are CYP3A4 substrates [6, 14] . However, avoidance of aprepitant due to potential interactions with antineoplastic therapy may open patients to uncontrolled CINV. There is, however, no comprehensive, systematic assessment of the literature describing the extent of interaction between aprepitant or fosaprepitant and other drugs. The primary objective of this systematic review was to describe the pharmacokinetic disposition of drugs co-administered with aprepitant or fosaprepitant using a standard definition of clinical significance. Our secondary objective was to describe adverse events ascribed to a drug interaction with aprepitant or fosaprepitant. The results of this systematic review will facilitate informed decision making regarding the selection of CINV prophylaxis.
Methods
The Preferred Reporting Items in Systematic Reviews and Meta-Analyses Protocols [15] and the Preferred Reporting Items in Systematic Reviews and Meta-Analyses guidelines [16] were followed in conducting this systematic review. Details on the search methods can be found in Supporting Information Appendix S1 (Tables S1 and S2 ). The publication selection, data extraction and quality assessment procedures are presented in Supporting Information Appendix S2.
We defined pharmacokinetic drug interactions as clinically significant according to the United States Food and Drug Administration (FDA) guidance document on drug interaction studies [17] . That is, an interaction was clinically significant when: (1) the geometric mean ratio (GMR) for the comparison of a victim drug's maximum concentration (C max ) in the presence vs. in the absence of aprepitant or fosaprepitant was greater than 1.25 or less than 0.80 or (2) the GMR for the comparison of the AUC of a victim drug in the presence vs. in the absence of aprepitant or fosaprepitant was greater than 1.25 or less than 0.80. This definition was based on the GMR for C max or AUC of the victim drug irrespective of the associated confidence interval (CI).
A significant adverse event was defined as an event where a patient experienced discomfort, harm or changes in a laboratory parameter that was indicative of an increased risk for harm that was highly suspected to have occurred due to co-administration of aprepitant or fosaprepitant with the patient's other medications. In the case of comparative studies, a high suspicion of interaction was defined as a statistically significant difference in the rate of the adverse event in the presence of aprepitant or fosaprepitant vs. the absence of aprepitant or fosaprepitant. The probability that the findings of case reports were a result of a drug interaction with aprepitant or fosaprepitant was determined using the Drug Interaction Probability Scale (DIPS) [18] . DIPS scores of 5 or greater indicate that a causal relationship between the adverse event and the drug interaction is probable or highly probable.
Results
Publication selection
Our literature search identified 4377 publications. Of these, 122 were brought to full text screening and 65 met criteria to be included in the qualitative synthesis. One publication [19] was excluded because it used methods that would affect the validity and generalizability of study findings. Hence, a total of 64 publications were included in the final synthesis (see Figure 1 ). Inter-screener agreement was substantial with a calculated kappa of 0.77 (95% CI: 0.65-0.88) [20] . The quality assessment of all included publications (case reports excluded) is reported in Supporting Information Appendix S3 (Tables S3-S5 ). The DIPS scores of included case reports are presented in Supporting Information Appendix S3 (Table S10) .
Publication characteristics
Of the 64 included publications, 34 evaluated pharmacokinetic interactions in adults (aprepitant/fosaprepitant and antineoplastic drug: 14 [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] ; aprepitant/fosaprepitant and non-antineoplastic drug: 20 [9, 11, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] ). Thirty-eight described adverse events in adults potentially resulting from drug interactions with aprepitant or fosaprepitant, eight of which also evaluated for a pharmacokinetic aprepitant/ fosaprepitant drug interaction (aprepitant/fosaprepitant and antineoplastic drug: 24 [23, 25, 33, ; aprepitant and non-antineoplastic drug: 14 [35, 43, 46, 51, 52, [74] [75] [76] [77] [78] [79] [80] [81] [82] ). In all, 27 victim drugs were evaluated for pharmacokinetic interaction with aprepitant or fosaprepitant and an adverse event was ascribed by study authors to an interaction with aprepitant or fosaprepitant for 15 victim drugs. Table 1 summarizes the characteristics of included publications. Complete data summary tables are provided in Supporting Information Appendix S3 (Tables S6-S9 ). A summary of findings are presented in Table 2 .
Pharmacokinetic interactions with aprepitant or fosaprepitant
Antineoplastic drugs. Thirteen included publications evaluated interactions between aprepitant and 10 individual antineoplastic drugs [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [32] [33] [34] and one publication evaluated an interaction between fosaprepitant and ifosfamide [31] . Seven included publications reported a GMR for AUC or C max with and without aprepitant or fosaprepitant, which allowed assessment of clinical significance [27, [29] [30] [31] [32] [33] [34] . Of these, three interactions met criteria for clinical significance: bosutinib PO [34] , cabazitaxel IV [30] and cyclophosphamide IV [32] .
GMR for AUC and C max with/without aprepitant were not reported in the publications describing erlotinib (route not reported) [28] , ifosfamide IV [23] , melphalan IV [24] , pazopanib IV [25] , and thiotepa IV disposition [22] . However, significant differences in other pharmacokinetic parameters were reported for several of these drugs when coadministered with aprepitant. Changes in parameters indicative of reduced clearance were reported for CYP3A4 substrates in the presence of aprepitant: erlotinib (two-fold increase in the trough concentration) [28] , pazopanib IV (reduction of mean oral clearance by 24-37%) [25] and thiotepa IV (20% lower tepa exposure) [22] . In addition, ifosfamide clearance was increased by approximately 60% in the presence of aprepitant [23] .
Non-antineoplastic drugs. Twenty publications evaluated aprepitant or fosaprepitant interactions with 16 nonantineoplastic drugs [9, 11, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] . Interactions between fosaprepitant and dexamethasone PO [11] or midazolam PO [11] and between aprepitant and dexamethasone PO [44] , methylprednisolone IV [44] , midazolam PO/IV [9, 47, 49] , oxycodone PO [39] and tolbutamide PO [46] met criteria for clinical significance.
Multiple included publications evaluated aprepitant drug interactions with CYP probe drugs: midazolam PO/IV [9, 43, 47, 49] and tolbutamide PO [46, 47] , implying effects on CYP3A4 and CYP2C9, respectively. A significant interaction with a higher dose of aprepitant (125 mg on day 1) was consistently demonstrated [9, 43, 47, 49] . When a lower dose of aprepitant of 40 mg PO day 1, followed by 25 mg PO on days 2 and 3 was administered with midazolam PO, the interaction did not meet criteria for clinical significance (GMR AUC 0-inf 1.22; 95% CI: 0.93-1.61 on day 1) [9] . Similarly, when a lower aprepitant dose of 40 mg was administered with tolbutamide PO, the interaction did not meet criteria for significance (GMR AUC 0-inf 0.87, 90% CI: not reported on day 4) [46] .
Study authors did not report a GMR for AUC or C max when describing the co-administration of the following drugs with aprepitant: alcohol IV [51] , dexamethasone IV [45, 50] , prednisolone PO [42] , quetiapine PO [52] , tacrolimus IV [40] and paroxetine PO [35] . However, significant differences in other pharmacokinetic parameters were reported when aprepitant was co-administered with several of these drugs. Reduced clearance or measures indicative of reduced clearance were observed for victim drugs which are CYP3A4 substrates: dexamethasone IV (reduction of dexamethasone clearance by approximately 25% and 50% in presence of aprepitant 40 mg or 125 mg, respectively [45, 50] ), quetiapine PO (11-fold increase in plasma quetiapine concentration in presence of aprepitant [52] ) and tacrolimus IV (43% increase in mean dose-normalized tacrolimus concentration in presence of aprepitant [40] ). In addition, the arithmetic mean AUC 0-24h and C max of paroxetine, a CYP2D6 substrate, were reduced by approximately 25% and 20%, respectively, in the presence of aprepitant [35] .
Adverse events ascribed to interactions with aprepitant or fosaprepitant
Most (76%; 26/34) publications reporting pharmacokinetic data did not report adverse events attributed to an aprepitant/fosaprepitant drug interaction. Eight publications did report that certain adverse events occurred more frequently with concomitant aprepitant administration. Of these, only one provided P-values [51] and two were case reports [23, 52] . The results of these three publications are presented with the other publications evaluating adverse events attributed to aprepitant or fosaprepitant below.
Antineoplastic drugs. Twenty-four included publications reported adverse events attributed to co-administration of aprepitant or fosaprepitant and an antineoplastic agent (anthracyclines, bexarotene PO, dinaciclib IV, erlotinib, ifosfamide IV, and pazopanib IV) [23, 25, 33, [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] 72] . Of these, interactions between fosaprepitant and anthracyclines and aprepitant and ifosfamide IV were the suspected cause. Table 1 Study characteristics of included studies One prospective study [60] and six retrospective studies [55, 56, 61, 62, 64, 73] evaluated the incidence of phlebitis when fosaprepitant and anthracycline chemotherapy were administered via the same peripheral vein. Two of these studies compared the incidence of this adverse event in patients receiving anthracycline vs. non-anthracycline chemotherapy [55, 56] . In these studies, the reported odds ratios of having phlebitis with fosaprepitant and anthracycline therapy vs. fosaprepitant and platinum chemotherapy were 12.95 (95% CI: 5.74 to 29.2) [55] and 8.1 (95% CI: 2.0 to 31.9) [56] . Other studies comparing phlebitis rates with/ without fosaprepitant also noted statistically significant increases in phlebitis with fosaprepitant compared to aprepitant [62, 64, 73] .
Thirteen publications (six retrospective studies, nine case reports and one case series) [23, 53, 54, 57-59, 65-70, 72] evaluated neurotoxicity associated with the combination of ifosfamide and aprepitant/fosaprepitant. The interaction between aprepitant and ifosfamide was a probable cause of neurotoxicity in one of the nine case reports (DIPS: 6) [23] . Neurotoxicity was unlikely to be due to an interaction between ifosfamide and aprepitant/fosaprepitant in the remaining case reports (DIPS: <5) [59, 65, 66, 68, 72] . Results from the retrospective studies, four specifically evaluating the co-administration of ifosfamide IV with aprepitant/ fosaprepitant [57, 58, 69, 70] and two evaluating general risk factors for ifosfamide-induced neurotoxicity [54, 67] , did not demonstrate an increased likelihood of ifosfamide-induced neurotoxicity or encephalopathy in the presence of aprepitant/fosaprepitant.
Non-antineoplastic drugs. Fourteen included studies [35, 43, 46, 51, 52, [74] [75] [76] [77] [78] [79] [80] [81] [82] described potential drug interactions between aprepitant and alcohol IV, methadone PO, midazolam IV, oxycodone intranasal and PO, selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors PO (SSRIs/SNRIs), paroxetine PO, quetiapine PO, tolbutamide PO, and warfarin PO. A probable interaction was observed between aprepitant and alcohol IV [51] , oxycodone [78] , quetiapine PO [52] , SSRIs/SNRIs [75] and warfarin [76, 77, 79, 82] . A randomized crossover study evaluating the pharmacokinetics of alcohol IV with/without aprepitant also conducted psychomotor and cognitive function tests on its subjects. A statistically significant decline in function was found for immediate pattern recognition (P = 0.043) and adaptive tracking at 7.5 h (P = 0.043) when aprepitant was given concomitantly with alcohol IV. However, study authors concluded that these differences were not clinically relevant [51] .
A randomized crossover study examined the effects of aprepitant on the subjective and physiologic response to oxycodone in individuals with opioid abuse to identify whether neurokinin-1 receptor antagonists diminish the effects of opioids related to their abuse potential [78] . A statistically significant enhanced response to high oxycodone doses was noted in the presence of aprepitant with aprepitant increasing the 'high' that patients experienced (PO oxycodone: P = 0.39; intranasal oxycodone: P = 0.007) and the estimated street value of the oxycodone (PO oxycodone: P = 0.023; intranasal oxycodone: P = 0.004). A lower respiratory rate (PO oxycodone: P < 0.025; intranasal oxycodone: 0.005) and increased end tidal carbon dioxide (PO oxycodone: P = 0.028; intranasal oxycodone: P = 0.001) was also noted in the presence of aprepitant.
A case report suggested a probable interaction between quetiapine PO and aprepitant (DIPS: 6). Deep somnolence was reported when aprepitant was administered with quetiapine on days the patient was receiving chemotherapy [52] .
In addition, a retrospective, case-control study found that patients receiving aprepitant together with SSRIs/SNRIs PO had higher rates of National Cancer Institute-Common Toxicity Criteria version 3.0 (NCI-CTC v3.0) grade 2 or greater vomiting than a patient not receiving a SSRI or SNRI (P = 0.04) [75] .
One retrospective study and seven case reports described changes to International Normalized Ratio (INR) following the initiation of aprepitant administration in patients receiving chronic warfarin therapy [76, 77, [79] [80] [81] [82] . The retrospective study reported statistically significant increases in INR during the first week after aprepitant administration (P = 0.0000149) and significant decreases 2 weeks after aprepitant administration (P = 0.00069) vs. the week prior to aprepitant administration. The DIPS scores for four of these case reports indicated that an interaction between aprepitant and warfarin PO was probable [76, 77, 79] .
Discussion
Interactions between aprepitant/fosaprepitant and bosutinib PO [34] , cabazitaxel IV [30] , cyclophosphamide IV [32] , dexamethasone PO [11, 44] , methylprednisolone IV [44] , midazolam PO/IV [9, 43, 47, 49], oxycodone PO [39] and tolbutamide PO [47] were clinically significant as defined by the FDA [17] . In addition, clinical descriptions of adverse events probably or highly probably caused by coadministration of aprepitant or fosaprepitant with alcohol IV [51] , anthracyclines IV [55, 56, 60-62, 64, 73] , ifosfamide IV [23] , midazolam IV [43] , oxycodone intranasal and PO [78] , quetiapine PO [52] , SSRIs/SNRIs [75] and warfarin PO [76, 77, 79, 82] were identified.
Midazolam and tolbutamide are commonly used as probes in drug interaction studies to determine whether the investigated drug is an inhibitor or inducer of CYP3A4 or CYP2C9, respectively [17] . Included publications using midazolam PO support the classification of fosaprepitant as a weak CYP3A4 inhibitor [11] and aprepitant as a moderate CYP3A4 inhibitor [9] after the administration of the usual adult doses for CINV prevention. Delayed effects of aprepitant as a weak CYP3A4 inducer [47, 49] and a weak CYP2C9 inducer have also been noted several days after the administration of aprepitant [47] .
Interestingly, the information required to apply the FDA definition of a significant interaction was not provided in 40% (14/35) of included pharmacokinetic studies. However, in 10 of these 14 publications, significant differences in pharmacokinetic parameters other than GMR for C max or AUC were reported for the following victim drugs: dexamethasone IV, erlotinib (route not reported), ifosfamide IV, quetiapine PO, pazopanib PO, paroxetine PO, tacrolimus IV and thiotepa IV [22, 23, 25, 28, 35, 40, 45, 50, 52] . Hence, there is a possibility that these interactions may be clinically significant and caution is advisable when these drugs are administered with aprepitant.
In several instances (e.g. dinaciclib IV, ifosfamide, vinorelbine IV, dolasetron PO (poor metabolizers), granisetron PO, ondansetron IV and palonosetron IV), considerable variability in the GMR was observed and the upper or lower limit of the 90% CI exceeded the GMR threshold for clinical significance [27, 31, 33] . The FDA guidance document states that a drug interaction can be considered not to be clinically significant if the 90% CI for the systemic exposure ratios fall completely within 80 to 125% [17] . Thus, cases where the 90% CIs for the GMR for AUC or C max fall outside this range may be a cause for concern.
Cyclophosphamide IV merits discussion since pharmacokinetic data were not reported consistently across the three included publications that describe the co-administration of aprepitant and cyclophosphamide [21, 22, 32] . One of these three publications reported GMRs for AUC and C max with/without aprepitant and a designation of a clinically significant interaction was made based on this information [32] . Study authors for the other two publications did not report a clinically significant interaction. However, specific AUC and C max values were not reported in either of these publications and we were unable to draw conclusions based on our predefined definition [21, 22] .
Reports of the interaction between ifosfamide and aprepitant/fosaprepitant were also conflicting. While case reports [23, 59, 65, 66, 72] attributed ifosfamide-induced neurotoxicity to an aprepitant-ifosfamide drug interaction, only one case report had a DIPS score that would suggest that the interaction was the probable cause (DIPS score: 6) [23] . The included retrospective studies did not report P-values or demonstrate a statistically significant difference in ifosfamide-induced neurotoxicity rates in the presence of aprepitant [54, 57, 58, 67, 69, 70] . Furthermore, results from a randomized crossover trial reported GMRs for C max and AUC with/without fosaprepitant that did not meet our definition of a clinically significant interaction [31] . Large, prospective studies are required to determine risk factors, including the co-administration of aprepitant or fosaprepitant, for ifosfamide-induced neurotoxicity.
All of the victim drugs that were found to have a clinically significant pharmacokinetic interaction with aprepitant or fosaprepitant were CYP3A4 or CYP2C9 substrates, consistent with what is known about the pharmacology of aprepitant and fosaprepitant. However, several CYP3A4 or CYP2C9 substrates were found not to interact to a clinically significant extent with aprepitant or fosaprepitant. Co-administration of aprepitant and CYP3A4 substrates which were also substrates of p-glycoprotein or other efflux transporters (Supporting Information Appendix S4) often did not lead to significant changes in pharmacokinetic disposition. We speculate that, for these drugs, elimination via alternative pathways compensates for inhibition of CYP3A4 by aprepitant/fosaprepitant and mitigates the magnitude of the interaction.
Patient-related factors may also influence the magnitude of a CYP3A4-mediated drug interaction. Patients with increased sensitivity to CYP3A4 inhibition or with reduced capacity to compensate for CYP3A4 inhibition may be at higher risk of clinically significant interactions with aprepitant or fosaprepitant. For example, patients may have reduced CYP3A4 and hepatic drug transporter activity by virtue of their age, disease states, genotype or concurrent drug therapy. Patients with inflammatory conditions or cancer may also have reduced CYP3A4 capacity [83] . Young children may be particularly vulnerable since CYP3A4 concentrations steadily increase after birth and reach 30-40% of adult levels during the first year of life [84] . Similarly, the activities of potentially compensatory pathways such as hepatic drug transporters p-glycoprotein and organic anion-transporting polypeptide transporters increase with age [85] .
The strength of this systematic review is its rigorous approach to identify drug interaction publications, its application of a well-recognized definition of clinical significance of drug interactions and its use of a validated tool to assess the probability of adverse events described in case reports.
It is limited by the small sample size of many of the included studies and lack of power to detect differences in adverse events, as well as, at least for the non-antineoplastic victim medications, the conduct of many studies in healthy subjects. This limits the external generalizability of study results and was reflected in the quality assessment of included studies. Our ability to assess the clinical significance of pharmacokinetic interactions was also limited by the proportion of reports which did not present values for GMR for AUC or C max . With respect to the drug interaction studies reporting adverse events, an association between the reported adverse event and co-administration of aprepitant and a victim drug could not always be confirmed as a result of multiple confounding factors. For example, many of the studies evaluating ifosfamide-induced neurotoxicity were confounded by the presence of other potential risk factors, such as plasma albumin concentrations and co-administration of central nervous system acting agents. This ambiguity is reflected in the DIPS scores. Furthermore, the evaluation of adverse events related to drug interactions was limited to the timeframe of the studies. It is possible that changes in exposure to chemotherapy may have long-term consequences. No publication was identified that evaluated the long-term effects of an aprepitant/fosaprepitant drug interaction. This is an evidence gap that requires further investigation.
Despite these limitations, the findings of this systematic review are generalizable to adults with cancer since most studies (27/34) evaluated drug interactions after a single 125 mg dose of aprepitant or when given at the FDAapproved adult dose (Supplemental Tables S6-S9 ). The findings are also generalizable to most children since CYP3A4 activity approaches adult levels by early childhood.
Conclusion
Using systematic methods, we identified clinically significant interactions between aprepitant and fosaprepitant and 14 drugs. Administration of fosaprepitant and anthracycline antineoplastic agents via the same peripheral vein should be avoided. Dose adjustment of the victim drug or use of antiemetic agents other than aprepitant or fosaprepitant should be considered for patients receiving dexamethasone PO, methylprednisolone IV, midazolam PO/IV, oxycodone PO, or tolbutamide PO. We suggest that neurokinin-1 receptor antagonists without CYP3A4 activity be considered for patients receiving bosutinib PO, cabazitaxel IV or cyclophosphamide IV. Although less clear, the use of antiemetics other than aprepitant/fosaprepitant may be appropriate in patients receiving erlotinib, pazopanib IV or thiotepa IV. Our findings are summarized in Table 2 . Individuals with reduced capacity to metabolize drugs via CYP3A4 or other pathways, including neonates and young children, may be at higher risk of experiencing clinically significant interactions due to aprepitant/fosaprepitant drug co-administration. 
